Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $26.25.

Several equities analysts recently issued reports on SGMT shares. Wall Street Zen upgraded Sagimet Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Barclays assumed coverage on shares of Sagimet Biosciences in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $8.00 price objective for the company. Guggenheim started coverage on Sagimet Biosciences in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $27.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Sagimet Biosciences in a report on Wednesday, March 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Thursday, January 22nd.

Insider Buying and Selling at Sagimet Biosciences

In related news, CEO David Happel sold 12,101 shares of the company’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $5.36, for a total transaction of $64,861.36. Following the sale, the chief executive officer directly owned 677,621 shares of the company’s stock, valued at approximately $3,632,048.56. This represents a 1.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 14.70% of the company’s stock.

Institutional Trading of Sagimet Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. AlphaQuest LLC bought a new position in shares of Sagimet Biosciences during the third quarter worth about $804,000. American Century Companies Inc. boosted its holdings in shares of Sagimet Biosciences by 8.9% in the second quarter. American Century Companies Inc. now owns 42,285 shares of the company’s stock valued at $322,000 after acquiring an additional 3,454 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in shares of Sagimet Biosciences in the fourth quarter valued at approximately $316,000. BNP Paribas Financial Markets increased its stake in shares of Sagimet Biosciences by 9,168.2% during the second quarter. BNP Paribas Financial Markets now owns 26,785 shares of the company’s stock valued at $204,000 after acquiring an additional 26,496 shares during the period. Finally, XTX Topco Ltd raised its holdings in Sagimet Biosciences by 137.0% during the second quarter. XTX Topco Ltd now owns 25,624 shares of the company’s stock worth $195,000 after purchasing an additional 14,813 shares in the last quarter. 87.86% of the stock is currently owned by institutional investors and hedge funds.

Sagimet Biosciences Price Performance

SGMT opened at $5.24 on Thursday. The stock’s 50 day simple moving average is $5.44 and its 200 day simple moving average is $6.41. The stock has a market cap of $170.72 million, a P/E ratio of -3.34 and a beta of 3.17. Sagimet Biosciences has a 1-year low of $1.73 and a 1-year high of $11.41.

Sagimet Biosciences (NASDAQ:SGMT) last issued its quarterly earnings data on Wednesday, March 11th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14. Research analysts expect that Sagimet Biosciences will post -1.6 EPS for the current fiscal year.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.